Cyclooxygenase‐2 expression and relationship to tumour progression in human renal cell carcinoma

Hashimoto, Yoshitaka; Kondo, Yukihiro; Kimura, Go; Matsuzawa, Ichiro; Sato, Shigenori; Ishizaki, M; Imura, Nobumasa; Akimoto, Masao; Hara, Shuntaro

doi:10.1111/j.1365-2559.2004.01853.x

Cited by 37 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…COX-2 seems to play a role in carcinogenesis as well as in carcinoma progression; COX-2 is up-regulated in transformed cells [24], in colorectal cancers [20,22], ulcerative colitis-associated neoplasia [1], hepatocellular carcinoma [14], oesophageal and gastric carcinomas [25,34], pulmonary and mammary tumours [22], pancreatic cancer [27], renal cell carcinoma [11], prostate carcinoma [33] and pituitary tumours [30]. COX-2 knockout mice also have a lower incidence of several tumour types including skin papillomas and intestinal polyps [2,18,26].…”

Section: Introductionmentioning

confidence: 99%

Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland

et al. 2005

View full text Add to dashboard Cite

This study was undertaken to investigate cyclooxygenase-2 (COX-2) expression in follicular cells of the human thyroid. COX-2 expression was studied immunohistochemically in a total of 174 samples. COX-2 immunoreactivity was confined to the cell cytoplasm with the nuclei remaining unlabelled. COX-2 expression was observed in five cases (17.2%) of normal follicular cells and in one case (16.6%) of solid cell nests. Follicular carcinoma expressed COX-2 more frequently than follicular adenoma (93.4% vs 21.1%) (p

show abstract

Section: Introductionmentioning

confidence: 99%

Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland

et al. 2005

View full text Add to dashboard Cite

show abstract

“…COX-2 expression has been shown to be upregulated in various cancers [3][4][5][6] and RCC [7,8] . Like COX-2 inhibitors, several anticancer agents also mediate apoptosis in cancer cells and may share common intracellular pathways leading to apoptosis.…”

Section: Introductionmentioning

confidence: 99%

Enhancement of the Sensitivity of Renal Cell Carcinoma Cells to Fas-Mediated Cytotoxicity and Apoptosis by the Selective Cyclooxygenase-2 Inhibitor JTE-522

Sato¹,

Mizutani²,

Li³

et al. 2010

Urol Int

View full text Add to dashboard Cite

Background: Cyclooxygenase-2 (COX-2) is a key enzyme involved in the production of prostaglandins and its inhibitors have been shown to induce apoptosis in a variety of cancer cells. We reasoned that combination treatment of renal cell carcinoma (RCC) cells with COX-2 inhibitors and anticancer agents may result in synergistic apoptosis. We examined whether the selective COX-2 inhibitor JTE-522 synergizes with anticancer agents in cytotoxicity and apoptosis against RCC cells. Methods: The cytotoxicity of the selective COX-2 inhibitor JTE-522 and other anticancer agents against the RCC cell lines and the normal renal cell line was determined by the microculture tetrazolium dye assay. Results: JTE-522 was cytotoxic against the Caki-1 RCC cell line. JTE-522 and anti-Fas monoclonal antibody (CH-11) exhibited a synergistic cytotoxic effect against Caki-1 cells. In contrast, JTE-522 in combination with 5-fluorouracil, adriamycin, cis-diamminedichloroplatinum, or interferon-α, all commonly used clinically, resulted in an additive cytotoxic effect. Synergy achieved in cytotoxicity with JTE-522 and CH-11 was shown to be due to apoptosis. Conclusions: The present study demonstrated that the selective COX-2 inhibitor JTE-522 had a cytotoxic effect on RCC and that synergistic cytotoxicity against RCC was obtained with JTE-522 in combination with anti-Fas monoclonal antibody. These results suggest that selective COX-2 inhibitors in combination with immunotherapy may be useful in treating patients with RCC.

show abstract

“…For comparison, in the study of Miyata et al (2003), the criterion for positive COX-2 expression was 5%, whereas in the study of Kankuri-Tammilehto et al (2010), it was considered to be 10%. Also different antibodies have been used in other studies (Rini et al 2006, Cho et al 2005, Hashimoto et al 2004. This fact and the criteria for immunohistochemical classification may contribute to the difference in the results.…”

Section: Incidence Of P53 Ki-67 and Cox-2 Expressionsmentioning

confidence: 99%

Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions

Kankuri-Tammilehto¹

2012

Emerging Research and Treatments in Renal Cell Carcinoma

View full text Add to dashboard Cite

Cyclooxygenase‐2 expression and relationship to tumour progression in human renal cell carcinoma

Abstract: COX-2 overexpression within these intracellular organelles in RCC may be associated with renal cell carcinogenesis and COX-2 may be a useful biomarker in RCC.

Cited by 37 publications

References 26 publications

Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland

Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland

Enhancement of the Sensitivity of Renal Cell Carcinoma Cells to Fas-Mediated Cytotoxicity and Apoptosis by the Selective Cyclooxygenase-2 Inhibitor JTE-522

Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions

Contact Info

Product

Resources

About